Emerging data suggest Retatrutide , a dual agonist targeting both incretin and another hormone, appears to offer a promising development for obesity treatment. Initial human tests have shown considerable losses in abdominal tissue, possibly outperforming current body composition medications . Nevertheless , more evaluation is necessary to fully ass